- Home
- OBIO vs TEAF Comparison
OBIO vs TEAF Comparison
Compare OBIO & TEAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- TEAF
- Stock Information
- Founded
- OBIO 2017
- TEAF 2017
- Country
- OBIO United States
- TEAF United States
- Employees
- OBIO N/A
- TEAF N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- TEAF Trusts Except Educational Religious and Charitable
- Sector
- OBIO Health Care
- TEAF Finance
- Exchange
- OBIO Nasdaq
- TEAF Nasdaq
- Market Cap
- OBIO 200.1M
- TEAF 174.8M
- IPO Year
- OBIO N/A
- TEAF N/A
- Fundamental
- Price
- OBIO $5.84
- TEAF $12.51
- Analyst Decision
- OBIO Strong Buy
- TEAF
- Analyst Count
- OBIO 4
- TEAF 0
- Target Price
- OBIO $15.75
- TEAF N/A
- AVG Volume (30 Days)
- OBIO 57.1K
- TEAF 56.1K
- Earning Date
- OBIO 11-12-2024
- TEAF 01-01-0001
- Dividend Yield
- OBIO N/A
- TEAF 9.20%
- EPS Growth
- OBIO N/A
- TEAF N/A
- EPS
- OBIO N/A
- TEAF N/A
- Revenue
- OBIO $2,647,000.00
- TEAF N/A
- Revenue This Year
- OBIO $7.68
- TEAF N/A
- Revenue Next Year
- OBIO $110.40
- TEAF N/A
- P/E Ratio
- OBIO N/A
- TEAF N/A
- Revenue Growth
- OBIO N/A
- TEAF N/A
- 52 Week Low
- OBIO $4.22
- TEAF $11.11
- 52 Week High
- OBIO $11.69
- TEAF $13.30
- Technical
- Relative Strength Index (RSI)
- OBIO 51.19
- TEAF 33.68
- Support Level
- OBIO $5.56
- TEAF $12.57
- Resistance Level
- OBIO $6.50
- TEAF $12.64
- Average True Range (ATR)
- OBIO 0.53
- TEAF 0.14
- MACD
- OBIO 0.00
- TEAF -0.04
- Stochastic Oscillator
- OBIO 56.58
- TEAF 7.67
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.